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Introduction: In chronic diseases such as chronic obstructive pulmonary disease (COPD),
patients may not perceive all of the benefits of drug therapy until withdrawal. Thus, we eval-
uated the effect of tiotropium withdrawal on clinical variables.
Methods: COPD subjects who participated in two identical 1-year, prospective, double-blind,
placebo-controlled studies of tiotropium 18 mg once daily who completed a 3-week visit
following discontinuation of therapy were included in this analysis. Outcomes measured
included dyspnea (transition dyspnea index [TDI]), Peak Expiratory Flow Rate (PEFR), health
status (St George’s Respiratory Questionnaire [SGRQ]), and rescue b2-agonist use.
Results: Overall, the tiotropium group exhibited significant improvements in clinical parame-
ters at the end of therapy. Of the entire cohort of 921 patients, 713 patients (77%) completed
3-weeks post-withdrawal evaluation. Patients in the tiotropium group had 1.1 unit worsening in
TDI, decreased in PEFR, health status and reduced b2-agonist medication following treatment
discontinuation, while the placebo group remained relatively stable.
Conclusions: The withdrawal of tiotropium results in worsening of COPD over a three-week
interval. There was no evidence of a rebound effect in response to tiotropium withdrawal.
Published by Elsevier Ltd.0 617 5256; fax: þ1 210 949
edu (S.G. Adams).
hed by Elsevier Ltd.Introduction
Chronic obstructive pulmonary disease (COPD) is
a preventable and treatable disease in which patients
experience a progressive decline in lung function, wors-
ening exercise capacity with increasing dyspnea and
Table 1 Patient characteristics at baseline of patients
who had a valid baseline measurement, and 3-week post-
treatment data (mean (SD) unless otherwise specified).
Tiotropium Placebo
Total 445 268
Female/Male (%) 34/66 37/63
Age (years) 65 (9) 65 (9)
Body mass
index (kg/m2)
27 (5) 27 (5)
Duration of COPD (years) 8.4 (7.1) 8.0 (6.8)
Smoker/Ex-smoker (%) 34/66 33/66
Smoking history: packs/year 61(29) 60 (32)
FEV1 (L) 1.02 (0.40) 1.02 (0.43)
FEV1 (% predicted)
a 37 (13) 37 (14)
Morning PEFR (L/min) 193 (92) 199 (106)
Evening PEFR (L/min) 206 (97) 213 (104)
BDI 6.1 (1.9) 6.4 (2.2)
SGRQ total score 46 (16) 45 (16)
SGRQ impact score 32 (17) 31 (17)
BDI: baseline dyspnea index; FEV1: forced expiratory volume in
1 s; FVC: forced volume capacity; PEFR: peak expiratory flow
rate; SGRQ; St. George’s Respiratory Questionnaire.
a ECCS criteria.
1416 S.G. Adams et al.frequent exacerbations.1,2 COPD is a worldwide cause of
morbidity and mortality which can be treated. Bronchodi-
lator medications are considered central to the manage-
ment of airway obstruction. Current treatment guidelines
recommend the use of long-acting bronchodilators, either
long-acting b2-agonist or anticholinergic, in symptomatic
patients with moderate air-flow obstruction.1,2
Due to the long-term nature of the disease, it is impor-
tant to consider clinical trials with prolonged durations of
exposure to evaluate the impact of therapeutic interven-
tions. Such long-term trials need to incorporate multiple
measurements of efficacy in COPD including questionnaires
such as the transition dyspnea index (TDI)3 and the St
George’s Respiratory Questionnaire (SGRQ),4 which are
often used to measure dyspnea and health-related quality
of life (HRQL). Similarly, the patient’s use of rescue b2-
agonist medication is often used as a surrogate for the
degree to which patients are symptomatic due to air-flow
limitation.
Tiotropium is an inhaled anticholinergic for the treat-
ment of COPD that leads to bronchodilation for at least 24
hours with once-daily dosing. This sustained bronchodila-
tion is due to the prolonged dissociation half life from the
muscarinic M3 receptor (approximately 35 h).
5 Two long-
term, 1-year, placebo-controlled studies in the United
States demonstrated that once-daily inhaled tiotropium
consistently improved lung function, dyspnea, HRQL and
rescue b2-agonist use compared with placebo over the
course of the study.6 In these studies, patients were invited
to be evaluated one additional time 3 weeks after
completing study medication. This follow-up visit provided
a valuable opportunity to prospectively assess the extent to
which patients were able to perceive the effects of treat-
ment withdrawal and to evaluate the effects of tiotropium.
In addition, this protocol provided outcome information
regarding treatment withdrawal as a measure of treatment
efficacy. Therefore, the purpose of this post-hoc analysis is
to assess the effect of tiotropium withdrawal on dyspnea
(TDI), health status (SGRQ), rescue b2-agonist use, and Peak
Expiratory Flow Rate (PEFR).
Methods
Study patients
Two identical clinical trials designed to evaluate the efficacy
and safety of tiotropium were combined and evaluated.
The trials used a prospective, randomized, double-blind
and parallel-group design. Tiotropium was administered
at 18 mcg once daily via the HandiHaler device (Boehringer
Ingelheim GmbH & Co. KG, Ingelheim, Germany). Fifty
clinical centers participated in these trials and each
center’s institutional review board approved the protocol.
All patients provided written informed consent prior to
participation.
Inclusion and exclusion criteria have been fully
described previously.6 Briefly, the study groups consisted of
outpatients of either gender who were at least 40 years of
age with a clinical diagnosis of COPD, as defined by the
American Thoracic Society.7 Participants were required to
have at least a 10-pack-year history of smoking, clinicallystable airway obstruction, an FEV1 less than 70% of the
forced vital capacity (FVC) and a post-bronchodilator FEV1
of less than 65% of the predicted normal value. Concomi-
tant use of as-needed albuterol (by metered dose inhaler),
theophylline (excluding 24-hour preparations), and inhaled
steroids were allowed throughout the study period. The use
of short-acting anticholinergics, oral b2-agonists, and long-
acting inhaled b2-agonists were not permitted during active
treatment, but were allowed after study medication was
withdrawn. Patients were excluded if they had a history of
asthma, allergic rhinitis, atopy, or a total blood eosinophil
count of more than 600/mm, required regular daytime
supplemental oxygen, were on corticosteroid doses
exceeding the equivalent of 10 mg of prednisone daily
during the month prior to entering the study, had a recent
history of myocardial infarction (1 year or less), hospitali-
zation for heart failure (3 years or less), cardiac arrhyth-
mias requiring drug therapy, symptomatic prostatic
hypertrophy, or narrow angle glaucoma.
Study protocol
Following a two-week baseline period, patients were
randomly assigned in a 3:2 ratio to receive either tio-
tropium (18 mg) or placebo.6 Patients were administered
active medication (tiotropium in lactose) or placebo
(lactose) by inhalation, one dose each morning in identical-
appearing capsules via a dry powder inhaler device
(HandiHaler). Three weeks after completion of study
medication, patients returned for a follow-up clinical
assessment. During this follow-up period, there were no
medication exclusions and tiotropium was not available at
the time of the study. Dyspnea was assessed using the TDI,3
health-related quality of life was measured using the
SGRQ,4 morning and evening Peak Expiratory Flow Rate
Table 2 Respiratory medications at 3-week post-treat-
ment follow-up visit.
Tiotropium,
N (%)
Placebo,
N (%)
Total evaluated at 3-week
post-treatment
445 268
Total taking pulmonary meds 381 (85.6) 229 (85.4)
Tiotropium (not available) 0 0
Ipratropium 7 (1.6) 3 (1.1)
Long-acting beta agonist 1 (0.2) 1 (0.4)
Oxygen 48 (10.8) 22 (8.2)
Systemic steroids 67 (15.0) 53 (19.7)
Inhaled steroids 173 (38.9) 94 (35.1)
Xanthines 96 (21.6) 65 (24.2)
Evaluation of withdrawal of maintenance tiotropium in COPD 1417(PEFR) was measured to provide an assessment of lung
function, and rescue b2-agonist use over the 3-week follow-
up period was recorded. For this study, we compared the
clinical data obtained on the last study day to the 3-week
follow-up visit data.
Statistical analysis
Data are presented as proportions or means (standard
deviation). Analysis of covariance (ANCOVA) was used to
compare the change in response over time in the two
treatment groups for last treatment day and 3-week follow-
up. Only those patients who had a valid baseline
measurement and had at least some post-treatment data
were included in the analysis. A TDI total score of at least
one unit was considered a clinically significant change in
activity-related dyspnea.3 A change in SGRQ score of at
least 4 units was considered to be a clinically significant
change in quality of life.4 Statistical significance was
considered at p< 0.05.Table 3 Efficacy outcomes [adjusted mean (SE)] from patient
treatment data. All variables except TDI focal score represent ch
Tiotropium
N Mean (SE)
(a) Last treatment day
TDI focal score 432 1.28 (0.13)
SGRQ total score 438 3.43 (0.57)
SGRQ impact score 438 2.63 (0.64)
Rescue medication [dose/day] 419 0.51 (0.12)
PEFR am [L/min] 315 35.0 (5.5)
PEFR pm [L/min] 255 32.2 (5.9)
(b) 3-week follow-up
TDI focal score 432 0.20 (0.14)
SGRQ total score 438 1.70 (0.57)
SGRQ impact score 438 0.21 (0.67)
Rescue medication [dose/day] 398 0.10 (0.12)
PEFR am [L/min] 298 22.3 (5.6)
PEFR pm [L/min] 245 8.25 (6.6)
Based on analysis of covariance with terms for pooled center, treatmResults
A total of 921 patients were enrolled (nZ 550 tiotropium;
nZ 371 placebo) in these two clinical trials.3 These post-hoc
analyses include data from 713 patients (tiotropiumZ 445,
placebo 268) who have valid baseline measurements,
completed the trial, and had 3-week post-treatment data.
The baseline characteristics of the patients that completed
the 3-weeks post-treatment evaluation between groups are
similar (Table 1).
Because tiotropium was not commercially available at
the time of the study, no patients were taking this medi-
cation at the 3-week post-treatment follow-up visit. In
addition, there were no significant differences in respira-
tory medications at this final visit (Table 2).
Clinical parameters at last treatment day and 3-week
follow-up are summarized in Table 3a and b. On the last
treatment day, patients in the tiotropium group exhibited
improvements in clinical parameters compared with
patients in the placebo group.3 The improvement from
baseline in the morning and evening mean PEFR was
significantly greater for the tiotropium-treated group vs.
placebo on the last treatment day. The change from
baseline of b2-agonist dose per week was 3.57 for the
tiotropium-treated group and þ1.61 for the placebo group
on the last treatment day. However, at the 3-week follow-
up visit upon withdrawal of tiotropium, the mean scores
were similar for both groups (Fig. 1A and B). These values
were þ0.70 for the tiotropium-discontinuation group vs.
þ2.94 for the placebo-discontinuation group at the 3-week
follow-up visit (Fig. 2).
Assessment of dyspnea using TDI Focal scores is shown in
Fig. 3. A higher score denotes less dyspnea. Although the
mean TDI Focal scores in the tiotropium-treated group are
clinically and statistically higher than the placebo groups
on the last treatment day (1.28 vs. 0.25, respectively;
p< 0.001), the scores were similar at the 3-weeks who had a valid baseline measurement and 3-week post-
ange from baseline.
Placebo Difference p-value
N Mean (SE) Mean (SE)
264 0.25 (0.17) 1.03 (0.21) <.0001
263 0.00 (0.73) 3.43 (0.90) 0.0001
263 0.81 (0.82) 3.44 (1.01) 0.0007
259 0.23 (0.15) 0.74 (0.18) <.0001
198 16.9 (6.8) 18.2 (8.2) 0.0267
175 7.37 (7.0) 24.9 (8.5) 0.0036
264 0.39 (0.18) 0.19 (0.22) 0.3924
263 0.01 (0.73) 1.69 (0.90) 0.0601
263 0.91 (0.85) 1.12 (1.05) 0.2863
246 0.42 (0.15) 0.32 (0.18) 0.0815
190 22.5 (6.8) 0.21 (8.2) 0.9795
164 10.3 (7.7) 2.01 (9.3) 0.8289
ent and baseline as covariate.
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Figure 1 (A) Adjusted mean (SE) change in morning PEFR
(L/min) in the tiotropium (nZ 315/298) and placebo (nZ 198/
190) groups on the last treatment day and at the 3-week follow-
up. (B) Adjustedmean (SE) change in eveningPEFR (L/min) in the
tiotropium (nZ 255/245) and placebo (nZ 175/164) groups on
the last treatment day and at the 3-week follow-up.
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Figure 2 Adjusted mean (SE) change in rescue b2-agonist use
in the tiotropium (nZ 419/398) and placebo (nZ 259/246)
groups on the last treatment day and at the 3-week follow-up.
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Figure 3 Adjusted mean (SE) TDI focal scores in the tio-
tropium (nZ 432) and placebo (nZ 264) groups on the last
treatment day and at the 3-week follow-up.
1418 S.G. Adams et al.discontinuation follow-up visit (0.20 for the tiotropium-
discontinuation group vs. 0.39 for the placebo-discontinu-
ation group).
The mean change from baseline SGRQ Impacts and Total
scores for the tiotropium and placebo groups on the last
treatment day and at 3-week follow-up are shown in Fig. 4A
and B. Lower values represent improved health status.
Although not statistically significant, at the 3-week follow-
up there was a trend towards improved mean SGRQ Total
score (pZ 0.06) in the tiotropium-treated group.
Discussion
This secondary analysis from a prospective, randomized
study demonstrates for the first time that there is no
evidence of a rebound effect of dyspnea, PEFR, health
status, or rescue b2-agonist use in patients with COPD three
weeks after withdrawal of tiotropium. Patients in bothstudy groups had similar dyspnea scores three weeks after
the last treatment day. However, patients in the tio-
tropium-withdrawal group had trends towards improved
health status, reduced b2-agonist use and better PEFRs
compared with the placebo group despite discontinuation
of active therapy for three weeks.
Bronchodilators are considered first-line therapy in the
management of symptomatic COPD patients.1,2 Previously
reported clinical trials have demonstrated that tiotropium
improves lung function, dyspnea, exercise tolerance and
health status.6,8e11 In addition, clinical trials have shown
consistent effects on reducing exacerbations of COPD.12,13
These effects are due in part to the prolonged dissociation
half life from the muscarinic M3 receptor (approximately
35 h), giving tiotropium a mean plasma half life of about
one week.5 In this study, we demonstrated that some of the
tiotropium effects may be present for up to 3 weeks after
discontinuation of therapy. The more relevant effects were
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Figure 4 (A) Adjusted mean (SE) change in SGRQ impacts
scores in the tiotropium (nZ 438) and placebo (nZ 263)
groups on the last treatment day and at the 3-week follow-up.
(B) Adjusted mean (SE) change in SGRQ total scores in the
tiotropium (nZ 438) and placebo (nZ 263) groups on the last
treatment day and at the 3-week follow-up.
Evaluation of withdrawal of maintenance tiotropium in COPD 1419in patient’s quality of life assessments and the decreased
need of rescue b2-agonist.
This current study highlights the importance of therapy
discontinuation and patient compliance in the treatment of
COPD. Several studies have demonstrated an acute wors-
ening of patients’ symptoms after inhaled corticosteroids
(ICS) withdrawal.14e17 A recent report by Suissa et al.18
highlighted that a significant number of patients enrolled in
clinical trials of ICS in COPD have been conducted, at least,
in part in patients already taking these medications. These
investigators demonstrated a different clinical response in
patients who continue to use ICS and patients that dis-
continue ICS. These analyses support prior reports of
withdrawal effects after ICS are discontinued. Because
these withdrawal effects of ICS were unexpected, doc-
umenting whether or not a similar phenomenon occurs upon
the withdrawal of tiotropium is important. To our knowl-
edge this is the first clinical report of the effect of tio-
tropium withdrawal. Our study demonstrates that dyspneascores match the placebo group at three weeks after tio-
tropium withdrawal. However, those who were initially
randomized to the active treatment group required less
rescue use of b2-agonist and had better health-related
quality of life scores three weeks after withdrawal of study
medication. In addition, the worsening of symptoms in
those withdrawn from tiotropium emphasizes the need for
continuation of maintenance treatment.
There are several limitations to our analysis. Although,
not all the patients that were randomized in the clinical
trial completed the last treatment day and 3-week follow-
up visit, we were able to obtain data in the majority of
randomized patients. The 3-week follow-up period after
withdrawal of study medication does not represent long-
term follow-up; however, because the mean plasma half
life of tiotropium is approximately one week and there may
be sustained benefits on patient reported outcomes,
changes in dyspnea, health status, PEFR, and rescue b2-
agonist use can be evaluated within this period. Finally,
spirometry was not obtained at the follow-up visit,
although PEFR showed responsiveness to treatment and to
withdrawal of treatment.
The evaluation of the withdrawal of active treatment is
an effective technique for demonstrating the need for
continued maintenance therapy. Our data demonstrate
that some of the tiotropium effects on improved health
status and reduced b2-agonist medication may be present
for at least 3-weeks following discontinuation of therapy.
These results warrant further investigation into the
hypothesis that long-acting anticholinergics may have the
potential to exert either direct or indirect long-term
effects beyond smooth muscle relaxation in patients with
COPD.
Statement of Originality and Clinical Relevance: This
manuscript is original and is not being considered for
publication in any other journal. The relevance of this
manuscript is that it is the first to describe clinical char-
acteristics after withdrawal of a long-acting anticholinergic
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